Semaglutide, 2.4mg, Once Weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth With Prediabetes (IGT)/Early Type 2 Diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD)
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Sep 2023 Status changed from not yet recruiting to recruiting.
- 20 May 2023 Phase of the trial changed from Phase 3 to phase 2.
- 20 May 2023 Planned initiation date changed from 1 Jan 2023 to 1 Jul 2023.